29 May, 2019
Kista, May 29 2019. Chordate CEO Anders Weilandt participated in the live event “Småbolagsjakten Live” yesterday at GT30 in Stockholm. Our CEO Anders Weilandt presented our offering including the new indication on migrane.Watch the video and learn about both our offering in rinithis and in migrane. The presentation is made in Swedish.
For more information, please contact:Anders Weilandt, CEOanders.email@example.comTelefon: +46 (0) 733 87 42 77
If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.
For questions about Chordate's share price or other investment-related topics, please see if the answer is here.
For questions about the medical effects of the K.O.S treatment, please see if the answer is here.
To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.